Tianjin International Biomedical Joint Research Institute entered the "national team" of national major new drug creation

According to Tianjin International Biomedical Joint Research Institute, focusing on the major strategic needs of the country, the Institute has made a number of breakthrough achievements by focusing on independent innovation and research and development of new drugs such as cancer, diabetes, major infectious diseases, cardiovascular and cerebrovascular diseases Among them, the representative achievements are: In the aspect of cancer prevention and treatment: with the Joint Research Institute as the core carrier, Tianjin has set up a "major special anti-cancer plan", which has now supported 11 clinical projects, more than 60 pre clinical projects, and 1 / 3 of the national clinical projects have been settled in Tianjin; the "new use" of doxycycline, an "old drug", can be provided for clinical cancer patients through the research and development of translational medicine The anti-tumor angiogenesis and anti metastasis drugs with low price (cost about 0.1 yuan / tablet, market price about 10 times of the cost), high safety and small side effects are expected to obtain clinical approval in 2015; the first tumor early warning detection technology of incubation enterprise Kaixi Pharmaceutical (Tianjin) Co., Ltd has been listed and is undertaking the cancer early warning detection service in Beijing, Tianjin, Hebei and Shandong of North China In terms of prevention and treatment of major metabolic diseases: the project of "development of new type II diabetes drugs with high efficiency and low toxicity" with independent intellectual property rights can avoid side effects of existing drugs, which is suitable for patients to take for a long time, and is expected to become a new type of insulin sensitizer diabetes drugs, and will apply for clinical approval in 2016; the imported phase II clinical research project of the UK - "oral insulin capsule" ”Through the research and development of the oral administration system of recombinant human insulin, the oral administration of insulin will be realized, which can improve the treatment compliance of diabetic patients, control blood sugar and reduce complications The preparation production and pharmacodynamics research are being carried out in China; the project "new drug development for the treatment of acute hemolytic uremic syndrome" will become the first small molecular medicine for the effective treatment of intestinal hemorrhage in the world Relevant research results have applied for 2 national invention patents and submitted PCT international patent protection In the aspect of prevention and treatment of major infectious diseases, the "new anti HFMD (EV71) drug development" project has developed therapeutic antibodies against virus infection and replication, and it is expected to apply for clinical approval by the end of 2015, which will fill the gap in severe treatment of HFMD in the world at present, and its successful development can occupy more than 70% of the market share, and achieve an economic benefit of more than 100 million yuan per year A kind of broad-spectrum anti coronavirus drug "anti Feifei" is designed Its successful development will become the first anti-virus drug for SARS in the world, and provide a strategic security means for the country to cope with the SARS crisis, and effectively fill the gap of national security demand; "new drug development with HIV integrase as the target" project has developed a strong inhibitor for HIV integrase, Clinical approval documents will be applied for in 2016, and antiviral drugs with independent intellectual property rights will be obtained It is understood that Tianjin International Biomedical Joint Research Institute has undertaken more than 30 major projects implemented by the state, Tianjin and Binhai New Area, entered the "national team" of national major new drug creation, supported the research and development of 7 new drugs and 19 clinical approvals, and became the core base of biomedical research and development in Tianjin In addition, on January 31, 2015, the results of the "2014 China Science annual news person" selection activity jointly sponsored by China Science Journal, science net, medical science journal and science news magazine were officially announced Rao Zihe, academician of the Chinese Academy of Sciences, academician of the Third World Academy of Sciences and president of Tianjin International Biomedical Joint Research Institute, was the only one from Tianjin Scientists